2024
Vascular mimicry as a facilitator of melanoma brain metastasis
Provance O, Oria V, Tran T, Caulfield J, Zito C, Aguirre-Ducler A, Schalper K, Kluger H, Jilaveanu L. Vascular mimicry as a facilitator of melanoma brain metastasis. Cellular And Molecular Life Sciences 2024, 81: 188. PMID: 38635031, PMCID: PMC11026261, DOI: 10.1007/s00018-024-05217-z.Peer-Reviewed Original ResearchConceptsVascular mimicryBrain metastasesMouse model of metastatic melanomaIncreased risk of metastasisAssociated with tumor volumeMelanoma brain metastasesRisk of metastasisSurvival of miceFuture treatment regimensCell line modelsTumor suppressor pathwayMetastatic melanomaTumor volumeSolid tumorsTreatment regimensTumor typesPoor prognosisHippo tumor suppressor pathwayIncreased riskMouse modelDownstream targets YAPMelanomaMetastasisSuppressor pathwayTumor
2018
Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.Peer-Reviewed Original ResearchFinal results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.Peer-Reviewed Original Research
2013
Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas
Viray H, Bradley WR, Schalper KA, Rimm DL, Rothberg BE. Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas. Archives Of Pathology & Laboratory Medicine 2013, 137: 1063-73. PMID: 23899062, PMCID: PMC3963468, DOI: 10.5858/arpa.2012-0284-oa.Peer-Reviewed Original ResearchConceptsHMB-45Primary tumorCutaneous melanomaLarge seriesMelanoma-specific survivalMelanoma primary tumorsGroup of antigensLarge tissue microarrayClinicopathologic covariatesClinicopathologic criteriaPrognostic relevanceHistopathologic profileClinicopathologic correlatesAntigen expressionClinicopathologic parametersMelanoma markersTissue microarrayPositive expressionSurvival analysisMelanomaMelanS100Melanoma cellsBivariate associationsSignificant differences
2012
p16ink4a Expression in Benign and Malignant Melanocytic Conjunctival Lesions
Zoroquiain P, Fernandes BF, González S, Novais GN, Schalper KA, Burnier MN. p16ink4a Expression in Benign and Malignant Melanocytic Conjunctival Lesions. International Journal Of Surgical Pathology 2012, 20: 240-245. PMID: 22287653, DOI: 10.1177/1066896911435697.Peer-Reviewed Original ResearchConceptsConjunctival melanocytic lesionsImmunoreactive scoreMelanocytic lesionsGerman immunoreactive scoreMean immunoreactive scoreRoutine microscopic analysisMalignant melanocytic lesionsConjunctival melanomaConjunctival lesionsImmunohistochemical expressionImmunohistochemical studyMortality rateHigh metastasisLarge seriesMalignant melanocytic neoplasmsLesionsP16 expressionMelanomaGood markerNeviAdditional studiesMelanocytic neoplasmsAtypiaUnfavorable locationP16